

Clotting Factor Concentrate Supplies - Management - Full Clinical Guideline

Reference no.: CG-HAEM/2023/019

1. Introduction

This guideline covers the ordering, storage, stock control and recording of usage of clotting factor concentrate used to treat people with hereditary and acquired bleeding disorders.

2. Aim and Purpose

To enable the safe supply and monitoring of clotting factor concentrate including the avoidance of waste.

3. Definitions, Keywords

Haemtrack: a web based system enabling patients to record their concentrate usage and for this to be monitored by the haemophilia centre.

4. Main body of Guidelines

Clotting factor concentrate (CFC) is ordered, stored and stock controlled by Pharmacy. For emergency use a small amount is kept in 2 places around the Trust.

The products we stock are:

Haemophilia A

ADVATE (recombinant FVIII)

REFACTO (recombinant FVIII) NB Refacto use is being phased out.

Ultimately all Refacto patients will use Advate.

Elocta (extended half life)

Haemophilia B

BENEFIX (recombinant FIX)

ALPROLIX

FXIII deficiency

FIBROGAMMIN (plasma derived FXIII)

FX deficiency

OCTAPLEX (plasma derived concentrate containing FX, FII, FVII, and FIX, also used for reversing warfarin)

Acquired FVIII inhibitor

FEIBA (plasma derived Factor VIII Inhibitor Bypassing Activity – similar to Octaplex but with the factors deliberately activated)

Novoseven. Recombinant VIIa.

Type 2 von Willebrands disease (the vast majority of von Willebrands disease patients have type 1 disease, respond to desmopressin and should not usually need clotting factor concentrate)

Wilate (plasma derived FVIII and VW concentrate)

Veyvondi (recombinant VW concentrate)

Factor VII deficiency; Glanzmanns Thrombasthenia

Novoseven (rVIIa)

Pharmacy Stores keep the main stock but for emergency use a small amount is kept in 2 other places.

1. Blood issue fridge room on the 5th Floor, next door to blood bank: combination for fridge is 2244.

Refacto (recombinant factor 8 for haemophilia A): 5000 units

Advate, (recombinant factor 8 for haemophilia A): 5000 units

Benefix (recombinant factor 9 for haemophilia B): 10,000 units

Wilate (von Willebrand and Factor 8, plasma derived, for type 2 VWD): 5000 units

2. Childrens emergency dept - in a fridge in the room at the back of children's resus:

Advate: (recombinant factor 8 for haemophilia A): 5000 units

Benefix (recombinant factor 9 for haemophilia B): 10,000 units

Wilate: (von Willebrand and Factor 8, plasma derived, for type 2 VWD: 5000 units.

1. Ordering

Concentrate is ordered by the Chief Pharmacy Technician in Pharmacy Stores. The peripheral fridges are stocked and maintained by the haemophilia nurse specialist.

2. Storage.

Storage is managed according to Pharmacy Standard Operating Procedures SOP-DISPsop68 'Procedure requirements for the storage, maintenance, movement and Alarm breaches for all pharmacy cold store areas, pharmacy fridges/freezers and ambient storage areas'. (The peripheral fridge on the 5th floor is monitored by the Comark temperature monitoring system)

3. Stock Control

Stock control is managed according to the Pharmacy SOP 'Stock Control Policy & Procedure'. The peripheral fridges are stock controlled by the Haemophilia CNS liaising with the Chief Pharmacy Technician.

4. Prescription and delivery for patients on home treatment

Home treatment is prescribed by the Haemophilia Consultant on the electronic prescribing system on iCM. Prescriptions are reviewed every 6 months. Home delivery Suitable for printing to guide individual patient management but not for storage Review Due:Dec 2026

is via 'Blood Bikes'.

5. Arrangements for emergency 'out of hours' supply. Concentrate is available in the following 2 places 24/7:

Blood issue fridge room on the 5th Floor, next door to blood bank: combination for fridge is 2244.

Refacto (recombinant factor 8 for haemophilia A): 5000 units

Advate, (recombinant factor 8 for haemophilia A): 5000 units

Benefix (recombinant factor 9 for haemophilia B): 10,000 units

Wilate (von Willebrand and Factor 8, plasma derived, for type 2 VWD): 5000 units

Childrens emergency dept - in a fridge in the room at the back of children's' resus:

Refacto and advate - 5000 units each

Wilate 2000 units.

If more concentrate is needed it will be issued by the on-call pharmacist from Pharmacy Stores.

6. Recording issue of concentrate to patients:

Home treatment: patient details, batch numbers and quantity are recorded by pharmacy according to their stock control SOP.

Factor issued to the peripheral fridges are recorded by pharmacy according to their stock control SOP.

Factor removed from the peripheral fridges for patient use are recorded on a register on top of the fridge (name H/N, factor brand, batch number, quantity) and in the patient record

7. Recording use by patients, including on Haemtrack

All our patients are encouraged to used Haemtrack

8. Submission of data via NHD for national tenders coordinated by CMU

Data is sent to the NHD quarterly by the Haemophilia CNS.

If clotting factor is not available in Derby, contact Nottingham Haemophilia Centre or the relevant company:

Emergency numbers:

Royal Hallamshire 0114 271 1900 ask for on-call Haemophilia Consultant.

Advate (Baxter) - 01635 206265 ask for security

Benefix (Wyeth) – 08458505544

FEIBA (Baxter) - 01635 206265 ask for security.

Fibrogammin (CSL Behring) – 01444447400

Haemate P (CLS Behring) - 01444 447400

Kogenate (Bayer) - 01635563000

Novoseven (Novo nordisk) - 01889565652

Refacto (Pfizer) – 08003893455 (or 01455620200, or Manor Facilities 02476344130)

References:

SOP- DISPsop68. **Procedure requirements for the storage, maintenance, movement and Alarm breaches for all pharmacy cold store areas, pharmacy fridges/freezers and ambient storage areas.**

Pharmacy Standard Operating Procedures:
Stock Control Policy & Procedure

5. Documentation Controls

Development of Guideline:	Dr A McKernan
Consultation with:	Dominic Moore, Pharmacy technician, Emma Bush Haemophilia CNS
Approved By:	Thrombosis Group - 20/3/19 Reviewed A. McKernan - Dec 23 CDCS Division - Dec 2023
Review Date:	Dec 2026
Key Contact:	Angela McKernan